Comparative Study of Combination Therapy (Immunotherapy + Chemotherapy) Versus Chemotherapy Alone in Treatment Response, Relapse, and Reactivation of Leprosy

Authors

  • Dr. Supriya Banerji,Dr. Geeta Sharma,Dr. Richa Jain Author

DOI:

https://doi.org/10.48047/

Keywords:

Leprosy, Multidrug Therapy (MDT), Immunotherapy, Chemotherapy, Mycobacterium leprae, Relapse, Reactivation, MIP Vaccine, Cell-mediated Immunity, Host-directed Therapy, Dermatology, Combination Therapy

Abstract

Leprosy, or Hansen’s disease, remains a significant public health issue in many endemic regions, particularly in India, despite the success of multidrug therapy (MDT) in reducing disease burden over the past few decades. However, persistent challenges such as relapse

Downloads

Download data is not yet available.

References

WHO. Global leprosy update, 2022: assessing disease burden and preventive interventions. Weekly Epidemiological Record. 2023;98(36):421–440.

Sharma P, Misra RS, Kar HK, et al. Mycobacterium indicus pranii as an adjunct to multidrug therapy in leprosy improves clinical outcomes and reduces reactions. Lepr Rev. 2015;86(1):47–59.

Downloads

Published

2024-12-24

How to Cite

Dr. Supriya Banerji,Dr. Geeta Sharma,Dr. Richa Jain. (2024). Comparative Study of Combination Therapy (Immunotherapy + Chemotherapy) Versus Chemotherapy Alone in Treatment Response, Relapse, and Reactivation of Leprosy. History of Medicine, 10(2), 2198-2205. https://doi.org/10.48047/